



Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th

November 4, 2021

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 4, 2021-- Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting's Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m. Eastern Time in Boston, Massachusetts. During the company's 30-minute presentation, Cortexyme's chief medical officer Michael Detke, MD, PhD, and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, will provide additional GAIN Trial top-line results and analysis.

CTAD 2021 Late-Breaking Readout Roundtable Details

Title: Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer's Disease.

- Presenters: Michael Detke, MD, PhD, Cortexyme's chief medical officer and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, Professor of Neurology at the Alzheimer's and Memory Disorders Division of the Barrow Neurological Institute at Dignity Health/St. Joseph's Hospital and Medical Center.
- Authors: Michael Detke¹, Marwan Sabbagh², Mark Ryder³, Joanna Bolger¹, Dave Hennings¹, Vladimir Skljarevski¹, Shirin Kapur¹, Debasish Raha¹, Florian Ermini¹, Mai Nguyen¹, Ursula Haditsch¹, Kim Perry⁴, Kelly Ritch⁵, Suzanne Hendrix⁶, Sam Dickson⁶, Hatice Hasturk⁷, Sarah Horine¹, Craig Mallinckrodt¹, Leslie Holsinger¹, Casey Lynch¹, and Stephen Dominy¹.
- Access: Cortexyme's CTAD 2021 presentation will be accessible on Thursday, November 11, 2021, beginning at 11:35 a.m. Eastern Time via the company's Investor Relations website at ir.cortexyme.com, in addition to being accessible to CTAD registered meeting attendees in-person and on its [virtual platform](#).

¹Cortexyme - South San Francisco, CA (USA), ²Barrow Neurological Institute, Dignity Health/St. Joseph's Hospital and Medical Center - Phoenix, AZ (USA), ³UCSF - San Francisco, CA (USA), ⁴Innovative Analytics - Portage, MI (USA), ⁵Datafy Clinical R&D - Portage, MI (USA), ⁶Pentara Corporation - Millcreek, UT (USA), ⁷Forsyth Institute - Cambridge, MA (USA)

About Cortexyme

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Cortexyme's lead program targets a specific, infectious pathogen called *P. gingivalis* found in the brain of Alzheimer's patients and other organs and tied to degeneration and inflammation in humans and animal models. The company's causation evidence for Alzheimer's disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20211104005314/en/): <https://www.businesswire.com/news/home/20211104005314/en/>

Cortexyme Contact:

Stacy Roughan
Cortexyme, Inc.
Vice President, Corporate Communications & Investor Relations
ir@cortexyme.com

Source: Cortexyme, Inc.